Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven D Rhodes

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Pediatric Blood & Cancer|May 28, 2020
Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1Amy E Armstrong, Steven D Rhodes, Abbi Smith, et al.
Genes & Development|April 8, 2015
Oxygen-sensing PHDs regulate bone homeostasis through the modulation of osteoprotegerinColleen Wu, Erinn B Rankin, Laura Castellini, et al.
The Journal of Clinical Investigation|December 11, 2012
Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require ErkKarl Staser, Su-Jung Park, Steven D Rhodes, et al.
Stem Cell Reports|May 31, 2016
Loss of Asxl1 Alters Self-Renewal and Cell Fate of Bone Marrow Stromal Cell, Leading to Bohring-Opitz-like Syndrome in MicePeng Zhang, Caihong Xing, Steven D Rhodes, et al.
Molecular Cancer Therapeutics|September 19, 2019
Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of <i>Nf1</i>-Deficient MiceCiersten A Burks, Steven D Rhodes, Waylan K Bessler, et al.
Cancer Research Communications|March 20, 2025
PLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway-Deficient Acute Myeloid LeukemiaAditya S Sheth, Ka-Kui Chan, Sheng Liu, et al.
The Journal of Biological Chemistry|May 31, 2020
Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 1Julie A Mund, SuJung Park, Abbi E Smith, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 25, 2013
Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse modelSteven D Rhodes, Xiaohua Wu, Yongzheng He, et al.
Haematologica|March 26, 2017
An abnormal bone marrow microenvironment contributes to hematopoietic dysfunction in Fanconi anemiaYuan Zhou, Yongzheng He, Wen Xing, et al.
The Journal of Clinical Investigation|July 1, 2025
A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- miceSu Jung Park, Jodi L Lukkes, Ka-Kui Chan, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Pediatric Blood & Cancer|May 28, 2020
Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1Amy E Armstrong, Steven D Rhodes, Abbi Smith, et al.
Genes & Development|April 8, 2015
Oxygen-sensing PHDs regulate bone homeostasis through the modulation of osteoprotegerinColleen Wu, Erinn B Rankin, Laura Castellini, et al.
The Journal of Clinical Investigation|December 11, 2012
Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require ErkKarl Staser, Su-Jung Park, Steven D Rhodes, et al.
Stem Cell Reports|May 31, 2016
Loss of Asxl1 Alters Self-Renewal and Cell Fate of Bone Marrow Stromal Cell, Leading to Bohring-Opitz-like Syndrome in MicePeng Zhang, Caihong Xing, Steven D Rhodes, et al.
Molecular Cancer Therapeutics|September 19, 2019
Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of <i>Nf1</i>-Deficient MiceCiersten A Burks, Steven D Rhodes, Waylan K Bessler, et al.
Cancer Research Communications|March 20, 2025
PLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway-Deficient Acute Myeloid LeukemiaAditya S Sheth, Ka-Kui Chan, Sheng Liu, et al.
The Journal of Biological Chemistry|May 31, 2020
Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 1Julie A Mund, SuJung Park, Abbi E Smith, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 25, 2013
Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse modelSteven D Rhodes, Xiaohua Wu, Yongzheng He, et al.
Haematologica|March 26, 2017
An abnormal bone marrow microenvironment contributes to hematopoietic dysfunction in Fanconi anemiaYuan Zhou, Yongzheng He, Wen Xing, et al.
The Journal of Clinical Investigation|July 1, 2025
A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- miceSu Jung Park, Jodi L Lukkes, Ka-Kui Chan, et al.
Pageof 5